Ewing's sarcoma family of tumors: Current management

Oncologist

Volumn 11, Issue 5, 2006, Pages 503-519

  Bernstein, Mark ^a   Kovar, Heinrich ^b   Paulussen, Michael ^c   Randall, R Lor ^d   Schuck, Andreas ^e   Teot, Lisa A ^f   Juergens, Herbert ^g  

^a UNIVERSITY OF MONTREAL   (Canada)

^b CHILDREN'S CANCER RESEARCH INSTITUTE   (Austria)

^c UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^d UNIVERSITY OF UTAH   (United States)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adolescents and young adults; Bone cancer; Ewing's sarcoma; Multimodal therapy; Pediatrics

Indexed keywords

ACTIN; CD45 ANTIGEN; CD99 ANTIGEN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DESMIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; MYOGENIN; NEUROFILAMENT PROTEIN; PYROPHOSPHATE TECHNETIUM TC 99M; RNA BINDING PROTEIN EWS; TOPOTECAN; TRANSCRIPTION FACTOR ER81; TUMOR MARKER; VASCULOTROPIN; VINCRISTINE;

ANTIGEN EXPRESSION; ARTICLE; BONE BIOPSY; BONE MASS; BONE PAIN; CALCIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOMYOPATHY; CARDIOTOXICITY; CHROMOSOME 11; CHROMOSOME 22; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ELECTROLYTE DISTURBANCE; EWING SARCOMA; GENE TRANSLOCATION; HISTOPATHOLOGY; HUMAN; IMAGING SYSTEM; INFERTILITY; INTENSIVE CARE; LYMPHATIC SYSTEM; METASTASIS; NEUROBLASTOMA; NORTH AMERICA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PERIOSTEUM; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RHABDOMYOSARCOMA; STEM CELL TRANSPLANTATION; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; HUMANS; ONCOGENE PROTEINS, FUSION; PROTO-ONCOGENE PROTEIN C-FLI-1; RADIOTHERAPY DOSAGE; SARCOMA, EWING'S; SOFT TISSUE NEOPLASMS;

EID: 33646859458     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.11-5-503     Document Type: Article

References (157)

1. Gurney JG, Swensen AR, Bulterys M. Malignant bone tumors. In: Ries LAG, Smith MA, Gurney JG et al., eds. Cancer Incidence and Survival Among Children and Adolescents: United States SEER Program 1975-1995. Bethesda, MD: NIH, 1999:99-110.
2. Hense HW, Ahrens S, Paulussen M et al. [Descriptive epidemiology of Ewing's tumor - analysis of German patients from EICESS 1980-1997.] Klin Padiatr 1999;211:271-275. German.
3. Widhe B, Widhe T. Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J Bone Joint Surg Am 2000;82:667-674.
4. Sneppen O, Hansen LM. Presenting symptoms and treatment delay in osteosarcoma and Ewing's sarcoma. Acta Radiol Oncol 1984;23:159-162.
5. Craft AW, Cotterill SJ, Bullimore JA et al. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party. Eur J Cancer 1997;33:1061-1069.
6. Ferrari S, Bertoni F, Mercuri M et al. Ewing's sarcoma of bone: relation between clinical characteristics and staging. Oncol Rep 2001;8:553-556.
7. Henk CB, Grampp S, Wiesbauer P et al. [Ewing sarcoma. Diagnostic imaging]. Radiologe 1998;38:509-522. German.
8. Tateishi U, Gladish GW, Kusumoto M et al. Chest wall tumors: radiologic findings and pathologic correlation: part 2. Malignant tumors. Radiographics 2003;23:1491-1508.
9. Frouge C, Vanel D, Coffre C et al. The role of magnetic resonance imaging in the evaluation of Ewing sarcoma. A report of 27 cases. Skeletal Radiol 1988;17:387-392.
10. Cohen MD, Weetman RM, Provisor AJ et al. Efficacy of magnetic resonance imaging in 139 children with tumors. Arch Surg 1986;121:522-529.
11. Mankin HJ, Mankin CJ, Simon MA. The hazards of the biopsy, revisited. Members of the Musculoskeletal Tumor Society. J Bone Joint Surg Am 1996;78:656-663.
12. Ewing J. Diffuse endothelioma of bone. Proc N Y Pathol Soc 1921;21:17-24.
13. Horowitz ME, Tsokos MG, DeLaney TF. Ewing's sarcoma. CA Cancer J Clin 1992;42:300-320.
14. Tsokos M. Peripheral primitive neuroectodermal tumors. Diagnosis, classification, and prognosis. Perspect Pediatr Pathol 1992;16:27-98.
15. Dehner LP. Primitive neuroectodermal tumor and Ewing's sarcoma. Am J Surg Pathol 1993;17:1-13.
16. Fellinger EJ, Garin-Chesa P, Su SL et al. Biochemical and genetic characterization of the HBA71 Ewing's sarcoma cell surface antigen. Cancer Res 1991;51:336-340.
17. Ramani P, Rampling D, Link M. Immunocytochemical study of 12E7 in small round-cell tumours of childhood: an assessment of its sensitivity and specificity. Histopathology 1993;23:557-561.
18. Weidner N, Tjoe J. Immunohistochemical profile of monoclonal antibody O13: antibody that recognizes glycoprotein p30/32MIC2 and is useful in diagnosing Ewing's sarcoma and peripheral neuroepithelioma. Am J Surg Pathol 1994;18:486-494.
19. Navarro S, Cavazzana AO, Llombart-Bosch A et al. Comparison of Ewing's sarcoma of bone and peripheral neuroepithelioma. An immunocytochemical and ultrastructural analysis of two primitive neuroectodermal neoplasms. Arch Pathol Lab Med 1994;118:608-615.
20. Lizard-Nacol S, Lizard G, Justrabo E et al. Immunologic characterization of Ewing's sarcoma using mesenchymal and neural markers. Am J Pathol 1989;135:847-855.
21. Dierick AM, Roels H, Langlois M. The immunophenotype of Ewing's sarcoma. An immunohistochemical analysis. Pathol Res Pract 1993;189:26-32.
22. Shanfield RI. Immunohistochemical analysis of neural markers in peripheral primitive neuroectodermal tumor (pPNET) without light microscopic evidence of neural differentiation. Appl Immunohistochem Mol Morphol 1997;5:78-86.
23. Gu M, Antonescu CR, Guiter G et al. Cytokeratin immunoreactivity in Ewing's sarcoma: prevalence in 50 cases confirmed by molecular diagnostic studies. Am J Surg Pathol 2000; 24:410-416.
24. Ladanyi M, Bridge JA. Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol 2000;31:532-538.
25. Hill DA, O'Sullivan MJ, Zhu X et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol 2002;26:965-977.
26. Aurias A, Rimbaut C, Buffe D et al. [Translocation of chromosome 22 in Ewing's sarcoma]. C R Seances Acad Sci III 1983;296:1105-1107. French.
27. Turc-Carel C, Aurias A, Mugneret F et al. Chromosomes in Ewing's sarcoma. I. An evaluation of 85 cases of remarkable consistency of t(11;22)(q24;q12). Cancer Genet Cytogenet 1988;32:229-238.
28. Hattinger CM, Rumpler S, Strehl S et al. Prognostic impact of deletions at 1p36 and numerical aberrations in Ewing tumors. Genes Chromosomes Cancer 1999;24:243-254.
29. Hattinger CM, Potschger U, Tarkkanen M et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002;86:1763-1769.
30. Maurici D, Perez-Atayde A, Grier HE et al. Frequency and implications of chromosome 8 and 12 gains in Ewing sarcoma. Cancer Genet Cytogenet 1998;100:106-110.
31. Kovar H, Jug G, Aryee DN et al. Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors. Oncogene 1997;15:2225-2232.
32. Wei G, Antonescu CR, de Alava E et al. Prognostic impact of INK4A deletion in Ewing sarcoma. Cancer 2000;89:793-799.
33. Huang HY, Illei PB, Zhao Z et al. Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse. J Clin Oncol 2005;23:548-558.
34. Delattre O, Zucman J, Plougastel B et al. Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature 1992;359:162-165.
35. Zucman J, Delattre O, Desmaze C et al. Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes Cancer 1992;5:271-277.
36. Ambros IM, Ambros PF, Strehl S et al. MIC2 is a specific marker for Ewing's sarcoma and peripheral primitive neuroectodermal tumors. Evidence for a common histogenesis of Ewing's sarcoma and peripheral primitive neuroectodermal tumors from MIC2 expression and specific chromosome aberration. Cancer 1991;67:1886-1893.
37. Ladanyi M, Lewis R, Garin-Chesa P et al. EWS rearrangement in Ewing's sarcoma and peripheral neuroectodermal tumor. Molecular detection and correlation with cytogenetic analysis and MIC2 expression. Diagn Mol Pathol 1993;2:141-146.
38. Desmaze C, Zucman J, Delattre O et al. Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genet Cytogenet 1994;74:13-18.
39. Shing DC, McMullan DJ, Roberts P et al. FUS/ERG gene fusions in Ewing's tumors. Cancer Res 2003;63:4568-4576.
40. Marley EF, Liapis H, Humphrey PA et al. Primitive neuroectodermal tumor of the kidney - another enigma: a pathologic, immunohistochemical, and molecular diagnostic study. Am J Surg Pathol 1997;21:354-359.
41. Sezer O, Jugovic D, Blohmer JU et al. CD99 positivity and EWS-FLI1 gene rearrangement identify a breast tumor in a 60-year-old patient with attributes of the Ewing family of neoplasms. Diagn Mol Pathol 1999;8:120-124.
42. Sheaff M, McManus A, Scheimberg I et al. Primitive neuroectodermal tumor of the kidney confirmed by fluorescence in situ hybridization. Am J Surg Pathol 1997;21:461-468.
43. Kuroda M, Urano M, Abe M et al. Primary primitive neuroectodermal tumor of the kidney. Pathol Int 2000;50:967-972.
44. Mikami Y, Nakajima M, Hashimoto H et al. Primary pulmonary primitive neuroectodermal tumor (PNET). A case report. Pathol Res Pract 2001;197:113-119; discussion 121-122
45. Kie JH, Lee MK, Kim CJ et al. Primary Ewing's sarcoma of the suodenum: a case report. Int J Surg Pathol 2003;11:331-337.
46. Tokudome N, Tanaka K, Kai MH et al. Primitive neuroectodermal tumor of the transverse colonic mesentery defined by the presence of EWS-FLI1 chimeric mRNA in a Japanese woman. J Gastroenterol 2002;37:543-549.
47. Shek TW, Chan GC, Khong PL et al. Ewing sarcoma of the small intestine. J Pediatr Hematol Oncol 2001;23:530-532.
48. Maesawa C, Iijima S, Sato N et al. Esophageal extraskeletal Ewing's sarcoma. Hum Pathol 2002;33:130-132.
49. Colecchia M, Dagrada G, Poliani PL et al. Primary primitive peripheral neuroectodermal tumor of the prostate. Immunophenotypic and molecular study of a case. Arch Pathol Lab Med 2003;127:e190-e193.
50. Sinkre P, Albores-Saavedra J, Miller DS et al. Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor. Int J Gynecol Pathol 2000;19:127-132.
51. Kato K, Kato Y, Ijiri R et al. Ewing's sarcoma family of tumor arising in the adrenal gland - possible diagnostic pitfall in pediatric pathology: histologic, immunohistochemical, ultrastructural, and molecular study. Hum Pathol 2001;32:1012-1016.
52. Dedeurwaerdere F, Giannini C, Sciot R et al. Primary peripheral PNET/Ewing's sarcoma of the dura: a clinicopathologic entity distinct from central PNET. Mod Pathol 2002;15:673-678.
53. Cheung CC, Kandel RA, Bell RS et al. Extraskeletal Ewing sarcoma in a 77-year-old woman. Arch Pathol Lab Med 2001;125:1358-1360.
54. Daldrup-Link HE, Franzius C, Link TM et al. Whole-body MR imaging for detection of bone metastases in children and young adults: comparison with skeletal scintigraphy and FDG PET. AJR Am J Roentgenol 2001;177:229-236.
55. 18F] Fluorodeoxyglucose positron emission tomography predicts outcome for Ewing sarcoma family of tumors. J Clin Oncol 2005;23:8828-8834.
56. Paulussen M, Ahrens S, Burdach S et al. Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275-281.
57. Zoubek A, Ladenstein R, Windhager R et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int J Cancer 1998;79:56-60.
58. Schleiermacher G, Peter M, Oberlin O et al. Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J Clin Oncol 2003;21:85-91.
59. Avigad S, Cohen IJ, Zilberstein J et al. The predictive potential of molecular detection in the nonmetastatic Ewing family of tumors. Cancer 2004;100:1053-1058.
60. Ewing J. Further report of endothelial myeloma of bone. Proc N Y Pathol Soc 1924;24:93-100.
61. Jenkin RD. Ewing's sarcoma a study of treatment methods. Clin Radiol 1966;17:97-106.
62. Phillips RF, Higinbotham NL. The curability of Ewing's endothelioma of bone in children. J Pediatr 1967;70:391-397.
63. Hustu HO, Holton C, James D Jr et al. Treatment of Ewing's sarcoma with concurrent radiotherapy and chemotherapy. J Pediatr 1968;73:249-251.
64. Sutow WW, Vietti TJ, Fernbach DJ et al. Evaluation of chemotherapy in children with metastatic Ewing's sarcoma and osteogenic sarcoma. Cancer Chemother Rep 1971;55:67-78.
65. Rosen G, Wollner N, Tan C et al. Proceedings: disease-free survival in children with Ewing's sarcoma treated with radiation therapy and adjuvant four-drug sequential chemotherapy. Cancer 1974;33:384-393.
66. Gasparini M, Barni S, Lattuada A et al. Ten years experience with Ewing's sarcoma. Tumori 1977;63:77-90.
67. Jurgens H, Exner U, Gadner H et al. Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 1988;61:23-32.
68. Nesbit ME Jr, Gehan EA, Burgert EO, Jr. et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-1674.
69. Burgert EO Jr, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990;8:1514-1524.
70. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.
71. Craft A, Cotterill S, Malcolm A et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J Clin Oncol 1998;16:3628-3633.
72. Oberlin O, Deley MC, Bui BN et al. Prognostic factors in localized Ewing's tumours and peripheral neuroectodermal tumours: the third study of the French Society of Paediatric Oncology (EW88 study). Br J Cancer 2001;85:1646-1654.
73. Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J Clin Oncol 2001;19:1818-1829.
74. Kolb EA, Kushner BH, Gorlick R et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-3430.
75. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
76. Bacci G, Forni C, Longhi A et al. Long-term outcome for patients with non-metastatic Ewing's sarcoma treated with adjuvant and neoadjuvant chemotherapies. 402 patients treated at Rizzoli between 1972 and 1992. Eur J Cancer 2004;40:73-83.
77. Meyers PA, Krailo MD, Ladanyi M et al. High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J Clin Oncol 2001;19:2812-2820.
78. Aparicio J, Munarriz B, Pastor M et al. Long-term follow-up and prognostic factors in Ewing's sarcoma. A multivariate analysis of 116 patients from a single institution. Oncology 1998;55:20-26.
79. Carrie C, Mascard E, Gomez F et al. Nonmetastatic pelvic Ewing sarcoma: report of the French society of pediatric oncology. Med Pediatr Oncol 1999;33:444-449.
80. Bacci G, Ferrari S, Bertoni F et al. Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin Oncol 2000;18:4-11.
81. Schuck A, Ahrens S, Paulussen M et al. Local therapy in localized Ewing tumors: results of 1058 patients treated in the CESS 81, CESS 86, and EICESS 92 trials. Int J Radiat Oncol Biol Phys 2003;55:168-177.
82. Dunst J, Sauer R, Burgers JM et al. Radiation therapy as local treatment in Ewing's sarcoma. Results of the Cooperative Ewing's Sarcoma Studies CESS 81 and CESS 86. Cancer 1991;67:2818-2825.
83. Gebhardt MC, Jaffe K, Mankin HJ. Bone allografts for tumors and other reconstructions in children. In: Langlais F, Tomeno B, eds. Limb Salvage - Major Reconstructions in Oncologic and Nontumoral Conditions. Berlin: Springer-Verlag, 1991:561-572.
84. Shapiro MS, Endrizzi DP, Cannon RM et al. Treatment of tibial defects and nonunions using ipsilateral vascularized fibular transposition. Clin Orthop 1993:207-212.
85. Ozaki T, Hillmann A, Wuisman P et al. Reconstruction of tibia by ipsilateral vascularized fibula and allograft. 12 cases with malignant bone tumors. Acta Orthop Scand 1997;68:298-301.
86. Schulte M, Brecht-Krauss D, Werner M et al. Evaluation of neoadjuvant therapy response of osteogenic sarcoma using FDG PET. J Nucl Med 1999;40:1637-1643.
87. van der Woude HJ, Bloem JL, Hogendoorn PC. Preoperative evaluation and monitoring chemotherapy in patients with high-grade osteogenic and Ewing's sarcoma: review of current imaging modalities. Skeletal Radiol 1998;27:57-71.
88. Sato O, Kawai A, Ozaki T et al. Value of thallium-201 scintigraphy in bone and soft tissue tumors. J Orthop Sci 1998;3:297-303.
89. Reddick WE, Bhargava R, Taylor JS et al. Dynamic contrast-enhanced MR imaging evaluation of osteosarcoma response to neoadjuvant chemotherapy. J Magn Reson Imaging 1995;5:689-694.
90. Imbriaco M, Yeh SD, Yeung H et al. Thallium-201 scintigraphy for the evaluation of tumor response to preoperative chemotherapy in patients with osteosarcoma. Cancer 1997;80:1507-1512.
91. Schuck A, Hofmann J, Rube C et al. Radiotherapy in Ewing's sarcoma and PNET of the chest wall: results of the trials CESS 81, CESS 86 and EICESS 92. Int J Radiat Oncol Biol Phys 1998;42:1001-1006.
92. Sailer SL, Harmon DC, Mankin HJ et al. Ewing's sarcoma: surgical resection as a prognostic factor. Int J Radiat Oncol Biol Phys 1988;15:43-52.
93. Arai Y, Kun LE, Brooks MT et al. Ewing's sarcoma: local tumor control and patterns of failure following limited-volume radiation therapy. Int J Radiat Oncol Biol Phys 1991;21:1501-1508.
94. Donaldson SS, Torrey M, Link MP et al. A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group. Int J Radiat Oncol Biol Phys 1998;42:125-135.
95. Dunst J, Jurgens H, Sauer R et al. Radiation therapy in Ewing's sarcoma: an update of the CESS 86 trial. Int J Radiat Oncol Biol Phys 1995;32:919-930.
96. Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with Ewing's sarcoma. Cancer Chemother Rep 1962;23:55-60.
97. Pinkel D. Cyclophosphamide in children with cancer. Cancer 1962;15:42-49.
98. Granowetter L, Womer R, Devidas M et al. Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group - Children's Cancer Group phase III trial. Med Pediatr Oncol 2001;37:172.
99. Rosen G, Caparros B, Mosende C et al. Curability of Ewing's sarcoma and considerations for future therapeutic trials. Cancer 1978;41:888-899.
100. Kushner BH, Meyers PA, Gerald WL et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995;13:2796-2804.
101. Hayes FA, Thompson EI, Meyer WH et al. Therapy for localized Ewing's sarcoma of bone. J Clin Oncol 1989;7:208-213.
102. Meyer WH, Kun L, Marina N et al. Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J Clin Oncol 1992;10:1737-1742.
103. Marina NM, Pappo AS, Parham DM et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: a feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999;17:180-190.
104. Bacci G, Mercuri M, Longhi A et al. Neoadjuvant chemotherapy for Ewing's tumour of bone: recent experience at the Rizzoli Orthopaedic Institute. Eur J Cancer 2002;38:2243-2251.
105. Elomaa I, Blomqvist CP, Saeter G et al. Five-year results in Ewing's sarcoma. The Scandinavian Sarcoma Group experience with the SSG IX protocol. Eur J Cancer 2000;36:875-880.
106. Kung FH, Pratt CB, Vega RA et al. Ifosfamide/etoposide combination in the treatment of recurrent malignant solid tumors of childhood. A Pediatric Oncology Group Phase II study. Cancer 1993;71:1898-1903.
107. Miser JS, Kinsella TJ, Triche TJ et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol 1987;5:1191-1198.
108. Pratt CB, Luo X, Fang L et al. Response of pediatric malignant solid tumors following ifosfamide or ifosfamide/carboplatin/etoposide: a single hospital experience. Med Pediatr Oncol 1996;27:145-148.
109. EURO-E.W.I.N.G. Study Committee. EURO-E.W.I.N.G. 99 Study Manual - EUROpean Ewing Tumor Initiative of National Groups Ewing Tumor Studies 1999. Available at http://euro-ewing.uni-muenster.de/ewing99.html. Accessed February 22, 2006.
110. Womer RB, Daller RT, Fenton JG et al. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur J Cancer 2000;36:87-94.
111. Kushner BH, Kramer K, Meyers PA et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000;35:468-474.
112. Saylors RL 3rd, Stine KC, Sullivan J et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
113. Ladenstein R, Lasset C, Pinkerton R et al. Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT Solid Tumour Registry. Bone Marrow Transplant 1995;15:697-705.
114. Kinsella TJ, Glaubiger D, Diesseroth A et al. Intensive combined modality therapy including low-dose TBI in high-risk Ewing's sarcoma patients. Int J Radiat Oncol Biol Phys 1983;9:1955-1560.
115. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993;11:1482-1488.
116. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001;19:870-880.
117. Pinkerton CR. Intensive chemotherapy with stem cell support-experience in pediatric solid tumours. Bull Cancer 1995;82(suppl 1):61s-65s.
118. Meyers PA. High-dose therapy with autologous stem cell rescue for pediatric sarcomas. Curr Opin Oncol 2004;16:120-125.
119. Cangir A, Vietti TJ, Gehan EA et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-893
120. Sandoval C, Meyer WH, Parham DM et al. Outcome in 43 children presenting with metastatic Ewing sarcoma: the St. Jude Children's Research Hospital experience, 1962 to 1992. Med Pediatr Oncol, 1996;26:180-185.
121. Bizer VA, Timukhina VN, Afanasova NV. [Programs for the radiation and drug treatment of metastases of Ewing's sarcoma to the lungs in children]. Med Radiol (Mosk) 1983;28:8-12. Russian.
122. Dunst J, Paulussen M, Jurgens H. Lung irradiation for Ewing's sarcoma with pulmonary metastases at diagnosis: results of the CESS-studies. Strahlenther Onkol 1993;169:621-623.
123. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J Clin Oncol 1998;16:3044-3052.
124. Whelan JS, Burcombe RJ, Janinis J et al. A systematic review of the role of pulmonary irradiation in the management of primary bone tumours. Ann Oncol 2002;13:23-30.
125. Folkman J. Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 1972;175:409-416.
126. Vacca A, Iurlaro M, Ribatti D et al. Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 1999;94:4143-4155.
127. Klement G, Huang P, Mayer B et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-232.
128. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000;30:3-21.
129. Ahrens S, Hoffmann C, Jabar S et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative Ewing Sarcoma Study. Med Pediatr Oncol 1999;32:186-195.
130. Bacci G, Picci P, Ferrari S et al. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase - results of two sequential studies. Cancer 1998;82:1174-1183.
131. Klingebiel T, Pertl U, Hess CF et al. Treatment of children with relapsed soft tissue sarcoma: report of the German CESS/CWS REZ 91 trial. Med Pediatr Oncol 1998;30:269-275.
132. Ozaki T, Hillmann A, Hoffmann C et al. Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. A report from the Cooperative Ewing's Sarcoma Study. Cancer 1996;78:892-900.
133. Rodriguez-Galindo C, Billups CA, Kun LE et al. Survival after recurrence of Ewing tumors: the St Jude Children's Research Hospital experience, 1979-1999. Cancer 2002;94:561-569.
134. Burdach S. Treatment of advanced Ewing tumors by combined radio-chemotherapy and engineered cellular transplants. Pediatr Transplant 2004;8(suppl 5):67-82.
135. McLean TW, Hertel C, Young ML et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: the Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol 1999;21:486-493.
136. Shankar AG, Pinkerton CR, Atra A et al. Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. United Kingdom Children's Cancer Study Group (UKCCSG). Eur J Cancer 1999;35:1698-1704.
137. Nesbit ME Jr, Perez CA, Tefft M et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: an Intergroup Study. Natl Cancer Inst Monogr 1981;(56):255-262.
138. Leu KM, Ostruszka LJ, Shewach D et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gem citabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol 2004;22:1706-1712.
139. Burdach S, Meyer-Bahlburg A, Laws HJ et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003;21:3072-3078.
140. Frohlich B, Ahrens S, Burdach S et al. [High-dosage chemotherapy in primary metastasized and relapsed Ewing's sarcoma. (EI)CESS]. Klin Padiatr 1999;211:284-902. German.
141. Hawkins D, Barnett T, Bensinger W et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors. Med Pediatr Oncol 2000;34:328-337.
142. Kovar H, Ban J, Pospisilova S. Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. Semin Cancer Biol 2003;13:275-281.
143. Kovar H, Aryee DN, Jug G et al. EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro. Cell Growth Differ 1996;7:429-437.
144. Lambert G, Bertrand JR, Fattal E et al. EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice. Biochem Biophys Res Commun 2000;279:401-406.
145. Ouchida M, Ohno T, Fujimura Y et al. Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 1995;11:1049-1054.
146. Tanaka K, Iwakuma T, Harimaya K et al. EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells. J Clin Invest 1997;99:239-247.
147. Toretsky JA, Connell Y, Neckers L et al. Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides. J Neurooncol 1997;31:9-16.
148. Dohjima T, Lee NS, Li H et al. Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line. Mol Ther 2003;7:811-816.
149. Maksimenko A, Malvy C, Lambert G et al. Oligonucleotides targeted against a junction oncogene are made efficient by nanotechnologies. Pharm Res 2003;20:1565-1567.
150. Scotlandi K, Baldini N, Cerisano V et al. CD99 engagement: an effective therapeutic strategy for Ewing tumors. Cancer Res 2000;60:5134-5142.
151. Kuttesch JF Jr, Wexler LH, Marcus RB et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol 1996;14:2818-2825.
152. Dunst J, Ahrens S, Paulussen M et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998;42:379-384.
153. Le Vu B, de Vathaire F, Shamsaldin A et al. Radiation dose, chemotherapy and risk of osteosarcoma after solid tumours during childhood. Int J Cancer 1998;77:370-377.
154. Paulussen M, Ahrens S, Lehnert M et al. Second malignancies after Ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001;12:1619-1630.
155. Friedman DL, Meadows AT. Late effects of childhood cancer therapy. Pediatr Clin North Am 2002;49:1083-1106, x.
156. Nagarajan R, Neglia JP, Clohisy DR et al. Education, employment, insurance, and marital status among 694 survivors of pediatric lower extremity bone tumors: a report from the childhood cancer survivor study. Cancer 2003;97:2554-2564.
157. Fuchs B, Valenzuela RG, Inwards C et al. Complications in long-term survivors of Ewing sarcoma. Cancer 2003;98:2687-2892.